FMP
NFL Biosciences SA
ALNFL.PA
EURONEXT
NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. Its natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.
1.8 EUR
-0.04 (-2.22%)
About
ceo
Dr. Ignacio Faus M.B.A., Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://www.nflbiosciences.com
exchange
EURONEXT
Description
NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. Its natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.
CIK
N/A
ISIN
FR0014003XT0
CUSIP
N/A
Address
199 Rue Helene Boucher
Phone
33 4 11 93 76 67
Country
FR
Employee
4
IPO Date
Jul 5, 2021
Key Executives
